Published in Medical Letter on the CDC and FDA, December 25th, 2005
According to a report from the United States, "Drug development for the treatment of dementia and age-related cognitive decline has been slow to produce clinically viable alternatives to the two existing FDA-approved drug treatments, AChE inhibitors and the noncompetitive NMDA receptor antagonist, memantine. Recent human and preclinical animal studies suggest that phosphodiesterase type 5 (PDE5) inhibitors, already in clinical use for the treatment of erectile dysfunction in men, may have central cognitive enhancing effects."
"Recent behavioral pharmacological studies with rodents...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA